Venetoclax, for example, disrupts BCL2–BCL2 interactions to induce apoptosis in malignant cells [59], whereas Motixafortide antagonizes the CXCL12–CXCR4 axis to mobilize hematopoietic stem cells for the treatment of multiple myeloma [60]. This evidence concerns the gene BCL2 and plasma cell myeloma.